How have AXSM and PCVX total returns compared?

Over the past 5 years, AXSM delivered 41.40% and PCVX delivered 25.08% annualized total return. Past performance doesn't predict future results.

Axsome Therapeutics, Inc. (AXSM) vs Vaxcyte, Inc. (PCVX)

A side-by-side comparison of Axsome Therapeutics, Inc. and Vaxcyte, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

AXSM

Axsome Therapeutics, Inc.

$8.97B

$174.34HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

PCVX

Vaxcyte, Inc.

$9.63B

$66.70HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — AXSM vs PCVX

growth of $100 · dividends reinvested · last 6y

AXSM +144.4% (+16.1%/yr)PCVX +182.3% (+18.9%/yr)PCVX compounded faster over this window

AXSM PCVX

AXSM vs PCVX: by the numbers

•PCVX is the larger company ($9.63B vs $8.97B market cap).
•Both run net losses; PCVX's is the smaller (0.00% vs -24.68% net margin).

Metrics side by side

Valuation

Metric	AXSM	PCVX
P/S ratio	11.55	N/A
P/B ratio	107.70	3.49

Profitability

Metric	AXSM	PCVX
Gross margin	93.24%	0.00%
Operating margin	-24.28%	0.00%
Net margin	-24.68%	0.00%
ROE	-230.05%	-38.59%
ROIC	-50.82%	-40.65%

Growth (annualized)

Metric	AXSM	PCVX
Total return CAGR (5Y)	41.40%	25.08%

Frequently asked

How have AXSM and PCVX total returns compared?: Over the past 5 years, AXSM delivered 41.40% and PCVX delivered 25.08% annualized total return. Past performance doesn't predict future results.

Go deeper

Full AXSM analysis Full PCVX analysis Interactive comparison tool

Dig into the metrics

Axsome Therapeutics ROE Vaxcyte ROE Axsome Therapeutics operating margin Vaxcyte operating margin Axsome Therapeutics revenue growth Vaxcyte revenue growth Axsome Therapeutics free cash flow Vaxcyte free cash flow

Axsome Therapeutics & Vaxcyte appear in these rankings

Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.